Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction.

Kieran F DochertyJohn J V McMurrayPaul R KalraJohn G F ClelandNinian N LangMark C PetrieMichele RobertsonIan Ford

Published in: ESC heart failure (2024)

In the IRONMAN trial, there was a trend to a greater increase in haemoglobin with ferric derisomaltose in iron-deficient patients taking an SGLT2 inhibitor at baseline, as compared with those not taking one.

Keyphrases

iron deficiency
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
high dose
low dose
patient reported outcomes
phase ii